To the Editor Recent reports of loss of vision after injection of ocriplasmin for vitreomacular traction cite the substrates of this enzyme as fibronectin and laminin.1-3 Not surprisingly, these are the same substrates mentioned in the package insert for this enzyme and are its “intended” targets at the vitreoretinal interface.4 Speculation about the adverse effects of the enzyme focused exclusively on these substrates. The reason for vision loss appears to involve damage to the photoreceptor outer and inner segments, suggesting that ocriplasmin may have broader substrate specificity.
Beebe DC. Understanding the Adverse Effects of Ocriplasmin. JAMA Ophthalmol. 2015;133(2):229. doi:10.1001/jamaophthalmol.2014.4484
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: